Storage guidance: Because retatrutide is an investigational product, storage and handling requirements are defined by the trial sponsor, the pharmacy supplying the medication, and the Investigator's Brochure
Retatrutide is a 39-amino-acid synthetic peptide that engages three metabolic receptors simultaneously: the GLP-1 receptor, the GIP receptor, and the glucagon receptor
Phase 3 trials, such as TRANSCEND-T2D-1, have demonstrated clinically meaningful outcomes
SGLT2i and GLP-1 RA Therapy in Type 1 Diabetes and Reno-Vascular Outcomes: A Real-World Study
GLP-1RAs have been combined with glucose-dependent insulinotropic agonism, as well as glucagon agonism or amylin analogues to further enhance their metabolic benefits
1 Within the past decade, longer-acting GLP-1 RA formulations entered the market as once-weekly, self-administered injectable pens most notably, semaglutide